Today: 26 March 2026
Subscribe
Browse Category

NYSE:BROS 5 November 2025 - 7 December 2025

Dutch Bros (BROS) Stock Outlook 2026: Latest News, Price Targets, and Growth Risks as of December 7, 2025

Dutch Bros (BROS) Stock Outlook 2026: Latest News, Price Targets, and Growth Risks as of December 7, 2025

Dutch Bros shares closed at $58.43 on December 5, 2025, down 4% for the day but up 12% over the past month and 13% over the year. The company reported Q3 revenue of $423.6 million, up 25% year-over-year, and raised full-year guidance. Analysts lifted price targets to $70–$80+, while institutional buyers and insiders traded heavily. Valuation remains high, with a P/E ratio near 117.
7 December 2025

Stock Market Today

  • Innate Pharma Shares Slide on 55% Revenue Drop, Cash Runway Risks Ahead of Q1 2026 Results
    March 26, 2026, 9:00 AM EDT. Innate Pharma (IPH.PA) faces a sharp 55% decline in Q4 revenue, casting a shadow over its financial health ahead of Q1 results scheduled for 26 March 2026. The biotech's stock opened under pressure at €1.094, below its 50- and 200-day averages, signaling investor concern. With cash runway extending only to the end of Q3 2026, funding challenges loom as the company burns through cash at the current rate. The loss-making firm reports an EPS of -0.55 and a high debt-to-equity ratio of 5.25, raising questions about near-term liquidity. Key trial results, particularly for Monalizumab and Lacutamab, alongside partnership updates with AstraZeneca and Sanofi, remain critical catalysts. Traders should watch cash visibility, cost control, and management commentary closely to gauge Innate Pharma's path forward amidst sector headwinds and valuation pressures.
Go toTop